News

BioSpecifics has modified its previously announced agreement to lower future royalties’ payable on net sales of its injectable collagenase, Xiaflex, for Peyronie’s disease. The company said that it

The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund, Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital and Western Technology

Mr Papadopoulos will complement Regulus Therapeutics’s board of directors, which is comprised of industry leaders in drug discovery and development. Mr Papadopoulos retired as vice chairman of Cowen

The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different

These represent market opportunities potentially exceeding $600 million in annual revenue for Abraxis. The transaction includes an initial strategic investment, by Abraxis, in ProMetic of $7 million at

So far, the complete set of optimized synthetic human genes sold via Qiagen’s web portal GeneGlobe (QIAgenes) was designed for the production in E coli bacteria only. The

Mr Killin replaces Eugene Bomba, who will be leaving his position as CFO of the company to return to private practice. Justin Belobaba, president and CEO of Healthscreen,

CSL plans to deliver more than six million doses of Afluria and the majority of the supply will be in single-dose, thimerosal-free, pre-filled syringes. Afluria is indicated for

In this position, Dr Trave will expand Premier Research’s capabilities in the area of drug development consulting and strengthen capabilities in the oncology therapeutic area. Dr Trave will